Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Utility of IFN- As Biomarker in Central Neuropsychiatric Involvement in SLE.
Fragoso-Loyo, Hilda, Atisha-Fregoso, Yemil, Nunez-Alvarez, Carlos, LLorente-Peters, Luis, Sanchez-Guerrero, Jorge
An accurate indicator of central nervous system (CNS) involvement in SLE has not yet been identified. Aim: To assess the utility of interferon (IFN)-a in serum and cerebrospinal fluid (CSF) as biomarker of disease activity in central neuropsychiatric systemic lupus erythematosus (cNPSLE).
In 34 patients with cNPSLE, 44 non-NPSLE, 16 surgical-SLE, 4 primary-neuropsychiatric, and 25 non-autoimmune, serum and CSF samples were drawn at hospitalization, except non-NPSLE in whom only serum was studied. Six-months later, serum/CSF and serum samples were taken in 20 cNPSLE and 35 non-NPSLE patients. All patients were evaluated by the study rheumatologists and neurologists, at hospitalization and six months later using a standardized protocol. SLE activity (SLEDAI-2K) was assessed at hospitalization in all patients, and six-months later in cNPSLE and non-NPSLE. The central NP manifestations included: seizure disorders 13, severe refractory headache 7, acute confusional state 8, cerebrovascular disease 4, psychosis 1, and transverse myelitis 1. Interferon-a was detected by xMAP milliplex technology according to the protocol of milliplex MAP (Millipore) kits (LINCO, Millipore, Billerica, MA.).
The mean ± SD age of cNPSLE patients was 31.4±12.2 years, which was similar across study groups (p=0.46). SLEDAI-2K scores among cNPSLE, non-NPSLE, and SLE-surgical patients were 15.3±8.2, 12.4±8.2, 3.8±1.5, respectively.
INF-a levels in serum were higher in cNPSLE than non-autoimmune patients (P=0.02), but were similar to non-NPSLE and SLE-surgical groups. In CSF, IFN-a levels were higher in cNPSLE than in non-autoimmune patients (P = 0.03), and non-significantly higher than SLE-surgical and primary-neuropsychiatric.
Six months later, serum levels of IFN-a did not vary from baseline values despite a significant decrease in SLEDAI-2K score in cNPSLE and non-NPSLE patients. CSF levels of IFN-a in cNPSLE also remained stable. IFNa levels in serum and CSF showed a fair correlation rs = 0.25 (P = 0.07), but the correlation of both of them with cNPSLE activity was poor.
Serum and CSF IFN-a levels in cNPSLE are not higher than in patients with non-NPSLE hence, IFN-a is not a useful biomarker of CNS involvement in SLE.
To cite this abstract, please use the following information:
Fragoso-Loyo, Hilda, Atisha-Fregoso, Yemil, Nunez-Alvarez, Carlos, LLorente-Peters, Luis, Sanchez-Guerrero, Jorge; Utility of IFN- As Biomarker in Central Neuropsychiatric Involvement in SLE. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :1404